Erratum: Department of Error (Interstitial lung disease in connective tissue disorders (2012) 380(9842) (689–698), (S0140673612610794), (10.1016/S0140-6736(12)61079-4));Interstitial lung disease in connective tissue disorders

The Lancet

Volumn 380, Issue 9842, 2012, Pages 689-698

  Fischer, Aryeh ^a   Du Bois, Roland ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MUCIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; SURFACTANT PROTEIN D; TACROLIMUS;

ANTIBODY TITER; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; ERYTHROCYTE SEDIMENTATION RATE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LOEFFLER PNEUMONIA; LUNG BIOPSY; LUNG LAVAGE; LYMPHANGIOLEIOMYOMATOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMYOSITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS;

EID: 84865129018     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61669-9     Document Type: Erratum

References (73)

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classifi cation of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Lynch DA. Quantitative CT of fi brotic interstitial lung disease. Chest 2007; 131: 643-44.
3. Lynch DA, Travis WD, Muller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005; 236: 10-21.
4. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J 2006; 28: 893-96.
5. Fischer A. Interstitial lung disease: a rheumatologist's perspective. J Clin Rheumatol 2009; 15: 95-99.
6. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarifi cation. Chest 2010; 138: 251-56.
7. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 2008; 31: 11-20.
8. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33: 882-96.
9. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185: 1147-53.
10. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fi brosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-86.
11. Park JH, Kim DS, Park IN, et al. Prognosis of fi brotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-11.
12. Fischer A, Swigris JJ, Groshong SD, et al. Clinically signifi cant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008; 134: 601-05.
13. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019-27.
14. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fi brosis in scleroderma is nonspecifi c interstitial pneumonia. Sarcoidosis Vasc Diff use Lung Dis 2002; 19: 121-27.
15. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167: 1410-15.
16. Agusti C, Xaubet A, Roca J, Agusti AG, Rodriguez-Roisin R. Interstitial pulmonary fi brosis with and without associated collagen vascular disease: results of a two year follow up. Thorax 1992; 47: 1035-40.
17. Papiris SA, Vlachoyiannopoulos PG, Maniati MA, Karakostas KX, Constantopoulos SH, Moutsopoulos HH. Idiopathic pulmonary fi brosis and pulmonary fi brosis in diff use systemic sclerosis: two fi broses with diff erent prognoses. Respiration 1997; 64: 81-85.
18. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fi brosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-90.
19. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182-85.
20. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fi brosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
21. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
22. Raghu G, Collard HR, Egan JJ, et al. An offi cial ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fi brosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
23. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136: 1397-405.
24. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322-28.
25. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 25: 549-59, vii.
26. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103: 1152-58.
27. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012; 106: 1040-47.
28. Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specifi c autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009; 28: 611-13.
29. Corte TJ, Copley SJ, Desai SR, et al. Signifi cance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39: 661-68.
30. Fujita J, Ohtsuki Y, Yoshinouchi T, et al. Idiopathic non-specifi c interstitial pneumonia: as an "autoimmune interstitial pneumonia". Respir Med 2005; 99: 234-40.
31. Kinder BW, Collard HR, Koth L, et al
32. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140: 1292-99.
33. Mosca M, Neri R, Bombardieri S. Undiff erentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classifi cation criteria. Clin Exp Rheumatol 1999; 17: 615-20.
34. Mosca M, Tani C, Bombardieri S. Undiff erentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol 2007; 21: 1011-23.
35. Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undiff erentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol 2002; 29: 2345-49.
36. Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S. Undiff erentiated connective tissue diseases: the clinical and serological profi les of 91 patients followed for at least 1 year. Lupus 1998; 7: 95-100.
37. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al. Anti-th/ to-positivity in a cohort of patients with idiopathic pulmonary fi brosis. J Rheumatol 2006; 33: 1600-05.
38. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic diff erences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136: 23-30.
39. Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecifi c interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fi brosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899-905.
40. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic signifi cance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fi brosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213-17.
41. Nagai S, Kitaichi M, Itoh H, Nishimura K, Izumi T, Colby TV. Idiopathic nonspecifi c interstitial pneumonia/fi brosis: comparison with idiopathic pulmonary fi brosis and BOOP. Eur Respir J 1998; 12: 1010-19.
42. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic signifi cance of histopathologic subsets in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 1998; 157: 199-203.
43. Riha RL, Duhig EE, Clarke BE, Steele RH, Slaughter RE, Zimmerman PV. Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecifi c interstitial pneumonia. Eur Respir J 2002; 19: 1114-18.
44. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
45. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-89.
46. Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2012; 63: 3078-85.
47. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470-76.
48. Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fl uid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum 2012; 40: 73-88.
49. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profi les in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56: 2005-12.
50. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-98.
51. Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009; 36: 773-80.
52. Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diff use Lung Dis 2011; 28: 27-33.
53. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fi brosis. J Rheumatol 2004; 31: 1112-20.
54. Tashkin DP, Elashoff R, Clements PJ, et al. Eff ects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-34.
55. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23: 306-09.
56. Gerbino AJ, Goss CH, Molitor JA. Eff ect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008; 133: 455-60.
57. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as fi rst-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45: 1005-08.
58. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory poly myositis with inter stitial lung disease. Lancet 1999; 353: 1762-63.
59. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-44.
60. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-96.
61. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130: 30-36.
62. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefi t in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
63. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006; 354: 2707-09.
64. Nathan SD, du Bois RM. Idiopathic pulmonary fi brosis trials: recommendations for the jury. Eur Respir J 2011; 38: 1002-04.
65. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fi brosis: test properties and minimal clinically important diff erence. Am J Respir Crit Care Med 2011; 184: 1382-89.
66. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2011; 184: 459-66.
67. Khanna D, Brown KK, Clements PJ, et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 2010; 28 (2 suppl 58): S55-62.
68. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2005; 171: 1040-47.
69. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fi brosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-69.
70. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fi brosis. Cochrane Database Syst Rev 2010; 9: CD003134.
71. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fi brosis. Eur Respir J 2010; 35: 821-29.
72. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fi brosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-48.
73. du Bois RM, Nathan SD, Richeldi L, Schwarz M, Noble PW. Idiopathic pulmonary fi brosis: lung function is a clinically meaningful endpoint for phase 3 trials. Am J Respir Crit Care Med 2012; published online July 12. DOI:10.1164/rccm.201206-1010PP.